Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase.
Rumpel
Mathias
M
Friedrich
Thomas
T
Deininger
Michael W N
MW
D001549:Benzamides; D001808:Blood Vessels / Q000187:drug effects*; D001853:Bone Marrow / Q000098:blood supply; D016022:Case-Control Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate